Experiences of treatment of age related macular degeneration with concomitant myopia

Abstract

Purpose: to assess the changes in visual functions in patients with age related macular degeneration (AMD) and medium to high degree myopia treated with a peptide bioregulator and a multivitamin complex. Material and methods. 60 patients (120 eyes) aged 44 to 79 with age-related changes in the retina treated with peptide bioregulator and/or multivitamin complex were tested for changes of visual functions. The patients, examined before and after treatment with both, were divided into 2 groups depending on treatment type (peptide plus multivitamin vs. multivitamin alone), which were further subdivided into two subgroups depending on the axial length of the eyeball (less than 26.5 mm vs. 26.5 mm or more). Results. A positive response to the therapy (increased visual acuity and improved perimetic parameters) was revealed in patients of both groups with AL < 26.5 mm), which may be accounted for by an initially better state of the retina. The patients of the subgroup with AL  26.5 mm) showed a significant improvement of uncorrected visual acuity, but best corrected visual acuity remained practically the same. Conclusions. The proposed treatment with a polypeptide bioregulator in combination with a multivitamin complex can be used in AMD and myopic patients with retinal pathology.

Keywords

• age-related macular degeneration
• myopia
• peptide bioregulators
• multivitamin complex